Cited by 648Nonmelanoma Skin Cancer StudiesSkin Protection and AgingHead and Neck Cancer Studies

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention

Chen, Andrew C., Martin, Andrew J., Choy, Bonita, Fernández-Peñas, Pablo, Dalziell, Robyn A., McKenzie, Catriona A., Scolyer, Richard A., Dhillon, Haryana M., Vardy, Janette L., Kricker, Anne, St. George, Gayathri, Chinniah, Niranthari, Halliday, Gary M., Damian, Diona L.·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1506197

Open this paper in CoChat — free account

Abstract

BACKGROUND: Nonmelanoma skin cancers, such as basal-cell carcinoma and squamous-cell carcinoma, are common cancers that are caused principally by ultraviolet (UV) radiation. Nicotinamide (vitamin B3) has been shown to have protective effects against damage caused by UV radiation and to reduce the rate of new premalignant actinic keratoses. METHODS: In this phase 3, double-blind, randomized, controlled trial, we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months. Participants were evaluated by dermatologists at 3-month intervals for 18 months. The primary end point was the number of new nonmelanoma skin cancers (i.e., basal-cell carcinomas plus squamous-cell carcinomas) during the 12-month intervention period. Secondary end points included the number of new squamous-cell carcinomas and basal-cell carcinomas and the number of actinic keratoses during the 12-month intervention period, the number of nonmelanoma skin cancers in the 6-month postintervention period, and the safety of nicotinamide. RESULTS: At 12 months, the rate of new nonmelanoma skin cancers was lower by 23% (95% confidence interval [CI], 4 to 38) in the nicotinamide group than in the placebo group (P=0.02). Similar differences were found between the nicotinamide group and the placebo group with respect to new basal-cell carcinomas (20% [95% CI, -6 to 39] lower rate with nicotinamide, P=0.12) and new squamous-cell carcinomas (30% [95% CI, 0 to 51] lower rate, P=0.05). The number of actinic keratoses was 11% lower in the nicotinamide group than in the placebo group at 3 months (P=0.01), 14% lower at 6 months (P<0.001), 20% lower at 9 months (P<0.001), and 13% lower at 12 months (P=0.001). No noteworthy between-group differences were found with respect to the number or types of adverse events during the 12-month intervention period, and there was no evidence of benefit after nicotinamide was discontinued. CONCLUSIONS: Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients. (Funded by the National Health and Medical Research Council; ONTRAC Australian New Zealand Clinical Trials Registry number, ACTRN12612000625875.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1506197

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A systematic review of worldwide incidence of nonmelanoma skin cancer
Lomas, A., Leonardi‐Bee, J., & Bath-Hextall, F. J. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.10830.x · Cited by 1,943
The epidemiology of UV induced skin cancer
Armstrong, B. K., & Kricker, A. (2001) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/s1011-1344(01)00198-1 · Cited by 1,811
Self-citation
Cutaneous Squamous-Cell Carcinoma
Alam, M., & Ratner, D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441306 · Cited by 1,311
Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial
Green, A., Williams, G., Nèale, R., Hart, V., Leslie, D., Parsons, P., Marks, G. C., Gaffney, P., Battistutta, D., Frost, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12168-2 · Cited by 976
Prevalence and Costs of Skin Cancer Treatment in the U.S., 2002−2006 and 2007−2011
Guy, G. P., Machlin, S. R., Ekwueme, D. U., & Yabroff, K. R. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.08.036 · Cited by 871
Reduced melanoma after regular sunscreen use: randomized trial follow-up
Green, A. C., Williams, G. M., Logan, V., & Strutton, G. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7078 · Cited by 799
Reduction of Solar Keratoses by Regular Sunscreen Use
Thompson, S., Jolley, D., & Marks, R. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310143291602 · Cited by 782
Basal-Cell Carcinoma
Rubin, A. I., Chen, E. H., & Ratner, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044151 · Cited by 772
Prevention of Skin Cancer in Xeroderma Pigmentosum with the Use of Oral Isotretinoin
Kraemer, K. H., DiGiovanna, J. J., Moshell, A. N., Tarone, R. E., & Peck, G. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806233182501 · Cited by 574
Safety of high-dose nicotinamide: a review
Knip, M., Douek, I. F., Moore, W. P. T., Gillmor, H. A., McLean, A. E. M., Bingley, P. J., & Gale, E. A. M. (2000) · Diabetologia · doi:10.1007/s001250051536 · Cited by 423

Flagged first, then by citations

Show all 38 references

1 of the 38 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

Yarosh DB, 2004, Cutis, 74, 10
Moon TE, 1997, Cancer Epidemiol Biomarkers Prev, 6, 949
Marquez C, 2010, J Drugs Dermatol, 9, 753
Shuttleworth D, 1988, Q J Med, 68, 717

Sorted by citations

Items 401–500 of 646

Patients’ willingness to accept adverse event and cost tradeoffs from oral nicotinamide for reduced risk of non-melanoma skin cancer
Boeri, M., Skelsey, M. K., Schiro, J. A., Dozier, S. E., Glinert, R., & Okun, M. M. (2023) · Journal of Dermatological Treatment · doi:10.1080/09546634.2023.2247105 · Cited by 3
“…with a history of multiple NMSCs for an oral supplement to reduce the risk of future NMSCs. Nicotinamide at a dose of 500 mg bid significantly reduces the risk of NMSC in non-immunosuppressed patients with a history of multiple NMSC (3) and possibly elevates the risk of severe infection (4).”
Background
Identification and Validation of Nicotinamide Metabolism-Related Gene Signatures as a Novel Prognostic Model for Hepatocellular Carcinoma
Yang, S., Li, A., Lv, L., Duan, J., Zheng, Z., Yang, W., Zhuo, W., Min, J., & Wei, J. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s464709 · Cited by 3
Skin Cancer Care in US Veterans—Serving Those Who Served
Chang, M. S., Wheless, L., & Hartman, R. I. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.3024 · Cited by 3
Regulation of Stem Cell Function by NAD +
Feng, Y., Qiu, H., & Chen, D. (2025) · Physiology · doi:10.1152/physiol.00052.2024 · Cited by 3
A nicotinamide metabolism-related gene signature for predicting immunotherapy response and prognosis in lung adenocarcinoma patients
Wang, M., Wei, L., Zhou, F., Wang, Z., Jia, X., & Han, X. (2025) · PeerJ · doi:10.7717/peerj.18991 · Cited by 3
“An accumulating body of evidence supports the involvement of NAM in cancer prevention and treatment ( Chen et al., 2015 ).”
Dermoscopic Aspects of Cutaneous Melanoma and Non-Melanoma Skin Cancer
Escobar, G. F., Pauvels, L. S. P., & Bakos, R. M. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128341374250310055950 · Cited by 3
Efficacité et innocuité des écrans solaires pour la prévention du cancer de la peau
Sander, M., Sander, M., Burbidge, T., & Beecker, J. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.201085-f · Cited by 2
Effect of Solvent Polarity on the Absorption and Fluorescence Spectra of Nicotinamide: Determination of Ground and Excited State Dipole Moments
Gebreyohanes, A. A., Belay, A., & Alemu, G. (2022) · East European Journal of Physics · doi:10.26565/2312-4334-2022-4-20 · Cited by 3
Oral Supplements and Dermatology: A Review
Reeves, R., & Lebowitz, E. (2024) · Dermatological Reviews · doi:10.1002/der2.239 · Cited by 4
Use of nicotinamide in dermatology
Diehl, C. (2019) · Ukrainian Journal of Dermatology Venerology Cosmetology · doi:10.30978/ujdvk2019-4-85 · Cited by 3
Sunscreen-Based Skin Protection Against Solar Insult: Molecular Mechanisms and Opportunities
Krajisnik, A., Perer, J., & Wondrak, G. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-15935-1_12 · Cited by 3
Klinisch‐pathologische Merkmale und histologische Tumorreste in Reexzisionspräparaten unvollständig resezierter Basalzellkarzinome
Lütgerath, C., Weiß, C., & Böer‐Auer, A. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14884_g · Cited by 3
Nicotinamide reduces new skin cancer risk
Sidaway, P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.199 · Cited by 3
Chemoprevention of basal cell carcinoma
Ali, F. R., Craythorne, E. E., & Al‐Niaimi, F. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14937 · Cited by 3
Skin Cancer: At-Risk Populations and Prevention
Noell, C. M., Aleissa, S., & Nguyen, B. (2018) · Springer eBooks · doi:10.1007/978-3-319-74903-7_1 · Cited by 3
Overlapping tumor‐specific expression of p53, p16INK4a, and sirtuin 1 in Bowen's disease: A case report
Takada, T. (2020) · Clinical Case Reports · doi:10.1002/ccr3.3400 · Cited by 3
Vitamins and Minerals in the Treatment of Acne Vulgaris
Marson, J. W., & Baldwin, H. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-58954-7_2 · Cited by 3
Chemopreventive potential of nicotinamide in Gilmore's Bayesian analysis
Phelan, P. S. (2018) · Australasian Journal of Dermatology · doi:10.1111/ajd.12849 · Cited by 3
Squamous Cell Carcinoma and its Precursors
Gupta, G., & Dirschka, T. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook140 · Cited by 3
Melatonin mitigates UV-induced tumorigenesis and suppresses hearing function deterioration in Xpa-deficient mice
Tsujimoto, M., Fujita, T., Furukawa, T., Arima, Y., Nibu, K., & Nishigori, C. (2025) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2025.01.003 · Cited by 2
Belatacept and non-melanoma skin cancer risk in kidney transplant recipients: a narrative review from a mechanistic and clinical perspective
Hennawy, H. M. E., Safar, O., Nassar, A., Madawie, M. Z. E., Zaitoun, M. F., Almahdi, Y. M., Faifi, A. S. A., & Tawhari, I. H. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04373-z · Cited by 2
“Niacinamide (vitamin B3), administered orally at 500 mg twice daily, has shown efficacy in reducing actinic keratoses and basal cell carcinoma in immunocompetent patients [65].”
Clinical evidence for the use of NAD+ precursors to slow aging
Khatri, S., Abdellatif, M., & Sedej, S. (2025) · Geromedicine · doi:10.70401/geromedicine.2025.0008 · Cited by 3
Skin Cancer in Solid Organ Transplant Recipients: A Review
van Ammers, M., & Chong, A. H. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01016-3 · Cited by 2
Changes in ultraviolet a radiation-induced thymidine dimers and erythema after oral nicotinamide or polypodium leucotomos extract in healthy volunteers: a randomized intraindividual trial
Faisal, A., Lerche, C. M., Douki, T., Philipsen, P. A., Pihl, C., Gregersen, T., Granborg, J. R., BJERRING, P., Hædersdal, M., & Wiegell, S. R. (2026) · Photochemical & Photobiological Sciences · doi:10.1007/s43630-026-00884-2 · Cited by 2
“In a randomized controlled trial including 386 immuno-competent patients who had previously had KC, oral NAM (500 mg twice daily for 12 months) reduced the incidence of KCs by 23% compared with placebo ( p = 0.02) [16].”
Influential
Hypervitaminosis: The deleterious effects of vitamins on the skin
Chen, M., & Driscoll, M. S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.04.011 · Cited by 2
NAD⁺ circuits in aging, tissue repair and fibrosis
Izadpanah, R., Rappaport, J., & Alt, E. U. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103305 · Cited by 5
Post-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspective
Gharote, M. A., & Deshpande, A. A. (2021) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_12_2021 · Cited by 2
The nicotinamide ruthenium(II) complex induces the production of reactive oxygen species (ROS), cell cycle arrest, and apoptosis in melanoma cells
Silva, H. V. R., Ferreira‐Silva, G. Á., Zavan, B., Machado, R. P., Honorato, J., Ellena, J., Ionta, M., Barbosa, M. I. F., & Doriguetto, A. C. (2022) · Polyhedron · doi:10.1016/j.poly.2022.116267 · Cited by 2
Analysis of metformin, niacinamide, and niacin as skin cancer preventative medications in solid organ transplant recipients
Linkous, C., Strat, N., Shope, C. N., Andrews, L. K., & Lee, L. W. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.10.023 · Cited by 2
[Translated article] Actinic Keratosis in Solid Organ Transplant Recipients: A Medical Literature Review
Vicente, A. M., Oteiza‐Rius, I., & Gil, L. A. (2024) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.10.045 · Cited by 2
“A diferencia de su uso pacientes inmunocompetentes donde sí parece haber una disminución de neoplasias cutá-neas (no de QA) 45,46 , recientemente se ha publicado la falta de diferencias signiﬁcativas en pacientes trasplantados al comparar nicotinamida (500 mg/12 h) con placebo, tanto en neoplasias…”
Background
Field cancerization in dermatology
Magalhães, R. F., Buffo, T. H., Gonçalves, H. D. S., Barcauí, C. B., & de Moraes, A. M. (2024) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.2024s113 · Cited by 2
“The authors described a reduction in the appearance of malignant epithelial tumors in patients who used nicotinamide 500 mg twice a day compared with placebo 5,20,21 .”
Background
Recent Research Trends against Skin Carcinoma - An Overview
Varshney, K., Mazumder, R., Rani, A., Mishra, R., & Khurana, N. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128307653240710044902 · Cited by 3
Minimally invasive modalities for keratinocyte carcinomas —Part II: Treatment
Gasek, N. S., Zhou, A. E., Gronbeck, C., Jain, N. P., Balboul, S., McMullan, P., Skudalski, L., Gulati, N., Ungar, J. P., Grant-Kels, J. M., et al. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.10.130 · Cited by 2
The evolving treatment landscape for CSCC
Miller, D. M. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-025-03933-5 · Cited by 2
“Nicotinamide, a form of vitamin B3, has demonstrated effectiveness in reducing new NMSCs in high-risk individuals with minimal adverse effects, making it an accessible option for chemoprevention [42].”
Evaluation of relationship between antihypertensive drug usage and dermatoscopic features in patients with keratinizing skin cancer
Demirdağ, H. G., & Tuğrul, B. (2021) · Dermatologic Therapy · doi:10.1111/dth.14957 · Cited by 2
“Oral nicotinamide was found safe and effective in reducing the rates of new BCC, cSCC and AK in high-risk patients compared to placebo.(41) The major limitation of our study was the minority of included cases.”
BackgroundInfluential
UV-Induced Chemokines as Emerging Targets for Skin Cancer Photochemoprevention
Byrne, S. N., & Halliday, G. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-43157-4_10 · Cited by 2
“This was directly investigated in a recent phase III, double-blind, randomized controlled trial where 386 participants who had a history of at least two NMSC received either 500 mg NAM or placebo twice per day in a 1:1 ratio for 12 months (Chen et al. 2015).”
MethodSelf-citation
The antitumor effects of mitochondria-targeted 6-(nicotinamide) methyl coumarin
Wang, H., Yao, M., & Xu, W. (2016) · Open Life Sciences · doi:10.1515/biol-2016-0070 · Cited by 2
Die Kopfhaut im Alter
Wroblewski, N., Wylon, K., & Ulrich, C. (2017) · Der Hautarzt · doi:10.1007/s00105-017-3988-2 · Cited by 2
Phytochemicals and Naturally Occurring Substances in the Chemoprevention of Skin Cancer
Higgins, S., Miller, K. A., Wojcik, K. Y., Ahadiat, O., Escobedo, L. A., Wysong, A. S., & Cockburn, M. (2017) · Current Dermatology Reports · doi:10.1007/s13671-017-0190-9 · Cited by 2
Effects of B Vitamins Overload on Plasma Insulin Level and Hydrogen Peroxide Generation in Rats
Sun, W. (2017) · The Chinese Journal of Physiology · doi:10.4077/cjp.2017.baf469 · Cited by 2
Molekulare Mechanismen der kutanen Photokarzinogenese: ein Update
Martens, M. C., Seebode, C., Lehmann, J., & Emmert, S. (2018) · Aktuelle Dermatologie · doi:10.1055/s-0043-122350 · Cited by 3
“Das Medikament findet bereits Verwendung bei der Behandlung von blasenbildenden Autoimmunerkrankungen wie dem bullösen Pemphigoid [36].”
Background
The management of numerous carcinomatous sequelae of human papilloma virus in an allogeneic stem cell transplant patient with chronic graft versus host disease
Williams, A., Gwinn, C., Iyer, J. G., Fleckman, P. H., & Shinohara, M. M. (2019) · JAAD Case Reports · doi:10.1016/j.jdcr.2018.11.010 · Cited by 2
“Nicotinamide (vitamin B3) has protective effects against ultraviolet damage and was found in a phase 3 trial to reduce the incidence of new squamous cell carcinomas by 30% after 12 months.(20) As with acitretin, no literature exists for the use of nicotinamide in chemoprevention of noncutaneous SCC.”
Background
Potential Association of Nicotinamide on the Telomerase Activity and Telomere Length Mediated by PARP-1 Mechanism in Myeloid Cancer
Muhammad, N. R., Ahmad, A., Nafi, S. N. M., Ahmad, F., Hamid, Z. A., & Sulong, S. (2020) · Sains Malaysiana · doi:10.17576/jsm-2020-4904-13 · Cited by 2
Dermatologic Manifestations of Nutritional Deficiency
Deutsch, A., & Manning, J. R. (2020) · Current Geriatrics Reports · doi:10.1007/s13670-020-00331-9 · Cited by 3
Kinetics of the Release of Nicotinamide Absorbed on Partially Neutralized Poly(acrylic-co-methacrylic acid) Xerogel under the Conditions of Simultaneous Microwave Heating and Cooling
Jovanović, J., & Adnadjevic, B. K. (2021) · Gels · doi:10.3390/gels7040193 · Cited by 2
“They are involved in many important biological oxidation-reduction reactions, among which is the production of adenosine triphosphate (ATP) [2].”
Background
Kognition und wortschatzarbeit
Pilzecker, B. (1996) · Zielsprache Deutsch · Cited by 2
Sonnenschutz der Zukunft: Herausforderungen und Möglichkeiten
Wolf, P., & Krutmann, J. (2022) · Der Hautarzt · doi:10.1007/s00105-022-04959-w · Cited by 2
A Review of Cutaneous Diseases Observed in Solid Organ Transplant Recipients.
Fronek, L. F., Giansiracusa, D., Nourmohammadi, N., Johnson, C., Yelich, A., & Hogan, D. J. (2022) · PubMed Central · Cited by 2
Nonmelanoma skin cancer
Rodriguez, S. Y. D. S. D. E., Enokihara, M. M. S. E. S., do Amaral, I. M., & Enokihara, M. Y. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15609-0.00035-0 · Cited by 2
Vitamin B3 – Not all forms are equivalent!
Hosseini, B. (2016) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1250 · Cited by 2
Nichtmelanozytäre Hauttumoren – von der aktinischen Keratose bis zum Plattenepithelkarzinom
Schmitz, L., Oster‐Schmidt, C., & Stockfleth, E. (2018) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13614_g · Cited by 2
Melanoma Prevention and Screening
Swetter, S. M., Geller, A. C., Leachman, S. A., Kirkwood, J. M., Katalinic, A., & Gershenwald, J. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-46029-1_6-1 · Cited by 2
Developing agents for the therapeutic prevention of melanoma: can the assessment of cutaneous precursor lesions help?
Maguire, W. F., & Kirkwood, J. M. (2020) · Future Oncology · doi:10.2217/fon-2020-0012 · Cited by 2
Confusion Among Different Forms of Vitamin B3
Ratnarajah, K., Zargham, H., & Jafarian, F. (2020) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475420936649 · Cited by 2
Current Practices for Preventative Interventions for Nonmelanoma Skin Cancers Among Dermatologic Surgeons
Arzeno, J., Leavitt, E. R., Lonowski, S. L., & Kim, J. J. (2021) · Dermatologic Surgery · doi:10.1097/dss.0000000000002909 · Cited by 2
“The lytic lesions are due to an imbalance in osteoclastic and osteoblastic functions and are eventually replaced with tumor.(4) A preoperative consultation is typically recommended before any surgical procedure.”
Background
Alternative treatment options for periocular basal cell carcinoma: a narrative review
Erikson, K., Brosig, A., Zimbelmann, M., Emmert, S., Guo, Y., Heindl, L. M., Adamietz, I. U. A., Ranjbar, M., Grisanti, S., & Kakkassery, V. (2021) · Frontiers of Oral and Maxillofacial Medicine · doi:10.21037/fomm-21-19 · Cited by 2
“The administration of 500 mg nicotinamide twice daily could reduce the formation of BCC in squama carcinoma patients by 20% (66).”
Background
Authors' response to a reply to ‘A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients’
Damian, D. L., Martin, A. J., Scolyer, R. A., Chen, A. C., & Halliday, G. M. (2016) · British Journal of Dermatology · doi:10.1111/bjd.15204 · Cited by 2
Self-citation
Response to ‘Considering the chemopreventive potential of nicotinamide in Gilmore's Bayesian analysis’
Gilmore, S. J. (2018) · Australasian Journal of Dermatology · doi:10.1111/ajd.12874 · Cited by 2
No Increased Risk of Major Adverse Cardiovascular Events following Nicotinamide ExposurePreprint
Wheless, L., Guennoun, R., Michalski-McNeely, B. M., Gonzalez, K. M., Weiss, R., Zhang, S., Yao, L., Madden, C., Chen, H., Triozzi, J. L., et al. (2024) · medRxiv · doi:10.1101/2024.09.16.24313743 · Cited by 2
“Nicotinamide is a water-soluble, activated form of vitamin B3 that is widely used as a chemopreventive agent against skin cancer 1–4 .”
A Novel NAD+ Supporting Supplement Increased NAD+ Levels, Improved Well-Being, and Alleviated Aging Symptoms: A Double-Blind, Placebo-Controlled StudyPreprint
Blomquist, S. A., Kelly, G., Adães, S., D’Adamo, C. R., Ardagh, A., Ramer, S., & Scuba, W. (2025) · medRxiv · doi:10.1101/2025.05.14.25327611 · Cited by 2
Oxidative Stress and Antioxidant Strategies in Human Diseases
Yuan, K., & Zhang, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-0522-2_1 · Cited by 2
Patient Perception of Skin Cancer Reduction by Nicotinamide Correlates With Use
Schneider, J. G., Majidian, M., & Moy, R. L. (2023) · Cureus · doi:10.7759/cureus.44403 · Cited by 1
“Nicotinamide enhances the rate of DNA repair, prevents UV-induced immunosuppression, and, in a seminal study, was shown to reduce the rate of non-melanoma skin cancers by 23% in a phase three, double-blind, randomized controlled trial published in the New England Journal of Medicine in 2015 [5-7].”
Background
Actinic Keratosis
Sendín‐Martín, M., & Conejo‐Mir, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-15130-9_2 · Cited by 1
Education and Perspectives on the Use of Oral Skin Cancer Chemoprophylaxis: A Cross-Sectional Survey of Current Fellows in Mohs Micrographic Surgery & Dermatologic Oncology
Guzman, A. K., Schmults, C. D., & Ruiz, E. S. (2023) · Dermatologic Surgery · doi:10.1097/dss.0000000000003962 · Cited by 1
“8 The administration of oral nicotinamide was further shown to reduce both AKs and the rate of new skin cancer development in a separate study.”
Background
Inhibition of UVB radiation‐induced tissue swelling and immune suppression by nicotinamide riboside and pterostilbene
Isak, V., Azizi, S., Zhou, X. K., Mehta, D., Ding, W., Bulmer, Z., Aivazi, D. S., Dellinger, R. W., & Granstein, R. D. (2024) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/phpp.12961 · Cited by 1
“50 Based on the data available, we formed the hypothesis that nic - otinamide riboside and pterostilbene can effectively inhibit deleterious effects of UV exposure on the skin.”
Background
A Curated and Updated Database of Pharmacological Skin Cancer Preventative Modalities
Pihl, C., Bjerring, P., Andersen, F., Hædersdal, M., & Lerche, C. M. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.06.1292 · Cited by 1
Autophagy and Intracellular Membrane Dynamics in Aging and Age-Related Diseases
Minami, S., Nakamura, S., & Yoshimori, T. (2025) · Learning materials in biosciences · doi:10.1007/978-3-031-88121-3_7 · Cited by 1
Squamous Cell Carcinoma
Lee, G. H., Taritsa, I. C., Ruiz, E. S., & LeBoeuf, N. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-82552-1_14 · Cited by 1
Examining the safety of nicotinamide for skin cancer prevention: Review of adverse events, metabolism, and toxic dosages
Xu, K. R., Belzberg, M., & Vidimos, A. T. (2025) · JAAD reviews. · doi:10.1016/j.jdrv.2025.07.009 · Cited by 1
Chemoprevention in Skin Cancer: What Advice?
Ortiz-Brugues, A., Cano, C. O., Corbella‐Bagot, L., Alamón‐Reig, F., Martí‐Martí, I., Ayguasanosa, M., Hernández-Santacana, M., Giavedoni, P., Aguilera, P., & Carrera, C. (2026) · Cancers · doi:10.3390/cancers18030436 · Cited by 1
“Randomized trials have shown a reduction in the rate of AKs and NMSC in high-risk patients [29,30].”
Chemoprevention of keratinocyte carcinomas and actinic keratoses in adults who were immunocompetent: a systematic review
Susanto, A., Morgan, E., Lindsay, D., & Collins, L. G. (2026) · Clinical and Experimental Dermatology · doi:10.1093/ced/llag073 · Cited by 1
Integrative approaches in skin cancer
Behl, D., Kashani-Sabet, M., Kim, K., Gomez-Yankellow, I., Kalakota, N., & Thompson, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30194-0.00041-2 · Cited by 1
Stimuli-responsive nicotinamide quaternary ammonium salts: Antimicrobial surfactants and profragrances with long-lasting scent
Chen, X., Tang, L., Wang, L., & Han, J. (2026) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2026.140252 · Cited by 1
Skin cancer and vitamins: In theory and practice
Wollina, U. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.04.005 · Cited by 1
Photoaging: Update on Pathogenesis, Prevention, and Treatment
Tsai, J., & Kang, S. (2026) · Annals of Dermatology · doi:10.5021/ad.26.006 · Cited by 1
“…recommended for chemoprevention of keratinocyte skin cancers due to its ability to reduce immunosuppression and enhance DNA repair in the context of UV exposure, and it has been found to demonstrate anti-photoaging properties against UVB and oxidative stress in human primary keratinocytes 59-61 .”
Skin Cancer Prevention and Antiaging: Role of Nicotinamide
Moro, F., Panebianco, A., Bartolocci, V., Capone, A., Guardo, A. D., Hyeraci, M., Gemma, G. P. A., Lella, G. D., Colonna, L., Ricci, F., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114918 · Cited by 1
“However, the strongest clinical evidence supporting NAM currently concerns NMSC [8], whereas evidence for NAM-based prevention in melanoma remains insufficient [9,10].”
Nicotinamide metabolism-related signature and lncRNA regulatory network in kidney renal clear cell carcinoma
Dong, P., Zhao, L., Shi, P., Ma, M., Huang, B., Wang, Z., 张少为, & Liu, H. (2026) · PeerJ · doi:10.7717/peerj.21300 · Cited by 1
Das Kutane Plattenepithelkarzinom
Leiter, U., & Nanz, L. (2026) · Die Onkologie · doi:10.1007/s00761-026-01970-x · Cited by 1
Mechanisms of Neurodegeneration and Retinal Imaging Biomarkers in Glaucoma
Siligato, A., Semeria, S., Gandolfi, F., Romani, V., Milano, G., & Triolo, G. (2026) · Neuroretina · doi:10.1007/s44448-026-00004-y · Cited by 1
“Preclinical findings, combined with evidence of reduced serum nicotinamide levels in patients with glaucoma and its favorable safety profile, have led to several clinical tri - als [26, 27].”
Optimizing Skin Health through Nutrition: Evidence-Based Insights
Bakshi, N., Loomba, V., & Soin, A. S. (2026) · Recent Progress in Nutrition · doi:10.21926/rpn.2603017 · Cited by 1
Vitamin B3 in der kosmetischen Dermatologie
Bayerl, C. (2017) · Aktuelle Dermatologie · doi:10.1055/s-0043-111513 · Cited by 1
“Entsprechend wurde zusammenfassend als Fazit dieser Studie die Einnahme des Präparates in Ergänzung zu Sonnenschutzmaßnahmen empfohlen [5].”
Background
Skin tumours in organ transplant recipients—implications for the plastic surgeon
Krapf, J., & Pierer, G. (2019) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-019-0504-7 · Cited by 1
Miscellaneous Systemic Drugs
Davis, L. S., & Owen, C. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-61211-1.00040-1 · Cited by 1
Aktinische Keratosen
Borik‐Heil, L., & Geusau, A. (2021) · hautnah · doi:10.1007/s12326-021-00419-9 · Cited by 1
Vorgehen bei kutanem Plattenepithelkarzinom
Onkologie, D. K. „. T. D. A. D., Leiter, U., Gutzmer, R., Alter, M., Ulrich, C., Meiwes, A., Heppt, M. V., Steeb, T., Berking, C., Lonsdorf, A. S., et al. (2021) · Der Onkologe · doi:10.1007/s00761-021-00938-3 · Cited by 1
Recurrent intraepidermal carcinoma of the scalp: A common skin malignancy presenting important management considerations on a high-risk site
Prakash, A., Muir, J., & Kennedy, D. (2021) · Australian Journal of General Practice · doi:10.31128/ajgp-07-20-5509 · Cited by 1
Clinicopathological features and histological tumor residues in re‐excision specimens of incompletely resected basal cell carcinomas
Lütgerath, C., Weiß, C., & Böer‐Auer, A. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14884 · Cited by 1
Glucose starvation impairs NER and γ-H2AX after UVB irradiation
Komaki, Y., Ono, S., Okuya, T., & Ibuki, Y. (2022) · Toxicology in Vitro · doi:10.1016/j.tiv.2022.105503 · Cited by 1
Aktuelles Management des Basalzellkarzinoms
Krieter, M., & Schultz, E. S. (2022) · Laryngo-Rhino-Otologie · doi:10.1055/a-1861-7077 · Cited by 1
“Durch die Einnahme soll das Risiko, an einem BZK zu erkranken, um bis zu 20% reduziert werden können [43].”
Background
Fotoinmunología: efectos inmunológicos de la radiación ultravioleta e implicaciones en dermatología
Meunier, L. (2023) · EMC - Dermatología · doi:10.1016/s1761-2896(23)47539-5 · Cited by 1
Bifunctional Antidiabetic - Anticancer Active Vitamins and Minerals: Drug Delivery Systems Enhancement
(2023) · Advances in Bioengineering and Biomedical Science Research · doi:10.33140/abbsr.06.01.002 · Cited by 1
Nahrungsergänzungsmittel
Smollich, M. (2023) · Elsevier eBooks · doi:10.1016/b978-3-437-23016-5.00005-2 · Cited by 1
Nanoliposomal amino acids counteracting protein malnutrition induced hematopoietic and hepatic complications
Ahmed, R. F., Elbaset, M. A., Farouk, H., Shabana, M. E.-A., Ahmed-Farid, O. A.-H., & Nasr, M. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105051 · Cited by 1
Sunlight, skin cancer and vitamin D
Mason, R. S., & Dixon, K. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91338-6.00043-4 · Cited by 1
Unconventional Remedies for Squamous Cell Carcinoma: A Journey into Alternative Treatments
Deng, E., & Khachemoune, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010286715240119061108 · Cited by 1
Elevated International Normalized Ratio After Initiation of Niacin and Niacinamide Chemoprophylaxis for Patients on Warfarin
Markham, D. J., Barbosa, N. S., & Degesys, C. A. (2024) · Dermatologic Surgery · doi:10.1097/dss.0000000000004144 · Cited by 1
From basic to clinical and therapeutic insights: news on actinic keratosis and skin squamous cell carcinoma
Cano, C. O., Suppa, M., Pastushenko, I., & del Mármol, V. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001115 · Cited by 1
Revisión del estado actual de las queratosis actínicas: etiopatogenia, diagnóstico y tratamientos disponibles
Cañueto, J., Turrión, L., & Ferrándiz‐Pulido, C. (2025) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2025.02.024 · Cited by 1
Keratinocyte cancer
Kjeldsen, E. W., Ortner, V. K., Rossau, A.-K., Andersen, F., Vinding, G. R., Lorentzen, H. F., Sølvsten, H., Togsverd‐Bo, K., Pallesen, K. A. U., Bjerring, P., et al. (2025) · Ugeskrift for Læger · doi:10.61409/v10240733 · Cited by 1
The advent of precision nutrigeroscience in cancer: from clinic towards molecular biology
Gao, Z., Liu, Y., Cui, Y., Han, Y., Cao, K., & Wu, Q. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.034 · Cited by 2
“The strongest evidence from phase 3 trials suggests that nicotinamide can be used prophylactically to prevent nonmelanoma skin cancer [36], and can also serve as an adjunct to radiotherapy in the treatment of bladder and laryngeal cancers [37,38].”

Authors: Chen, A. C., Martin, A. J., Choy, B., Fernández-Peñas, P., Dalziell, R. A., McKenzie, C. A., Scolyer, R. A., Dhillon, H. M., Vardy, J. L., Kricker, A., St. George, G., Chinniah, N., Halliday, G. M., & Damian, D. L.
Affiliations: The University of Sydney (AU)
ORCID: Chen, Andrew C.
Martin, Andrew J.
McKenzie, Catriona A.
Scolyer, Richard A.
Dhillon, Haryana M.
Vardy, Janette L.
Kricker, Anne
Halliday, Gary M.
Damian, Diona L.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-10-22
Volume: 373
Issue: 17
Pages: 1618-1626
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1506197
OpenAlex: W1852538637
Cited by: 648
References: 38
Citations by year: 2026: 53 · 2025: 66 · 2024: 59 · 2023: 74 · 2022: 61 · 2021: 75 · 2020: 55 · 2019: 57 · 2018: 49 · 2017: 51 · 2016: 38 · 2015: 4
FWCI: 37.14
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
Health Sciences › Medicine › Dermatology › Skin Protection and Aging
Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords: nicotinamide, nicotinic acid, skin cancer chemoprevention, non-melanoma skin cancer, basal cell carcinoma, squamous cell carcinoma, actinic keratosis, ultraviolet radiation, UV-induced DNA damage, NADPH oxidase, NADPH oxidase inhibitors, adverse events, drug safety, recurrence prevention, long-term follow-up
MeSH terms: Adult, Aged, Aged, 80 and over, Basal Cell Carcinoma, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Double-Blind Method, Female, Humans, Male, Middle Aged, Niacinamide, Skin Neoplasms, Vitamin B Complex, Secondary Prevention, Keratosis, Actinic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks